Otizm Spektrum Bozukluğunda Farmakolojik Tedaviler

Zeidan J, Fombonne E, Scorah J, et al. Global prevalence of autism: a systematic review upda- te. Autism Res. 2022; 15:778-790.

Autism Research Institute. Comorbidities of autism. 2021. Available from: https://www.autism.org/comorbidities-of-autism/.

MedicineNet. Types of autism medications and treatments. 2021. Available from:https:// www.medicinenet.com/types_of_autism_medications_and_treatments/drug-class.htm. Ac- cessed Feb 15, 2022.

DeFilippis M, Wagner KD. Treatment of autism spectrum disorder in children and adolescents. Psychopharmacol Bull. 2016; 46:18-41.

Autism Speaks. Medicines for treating autism’s core symptoms. 2022. Available from: https:// www.autismspeaks.org/medicines-treating-autisms-core-symptoms.

Lai MC, Kassee C, Besney R, et al. Prevalence of co-occurring mental health diagnoses in the autism population: a systematic review and meta-analysis. Lancet Psychiatry. 2019; 6:819- 829.

Hollander E, Phillips AT, Yeh CC. Targeted treatments for symptom domains in child and adolescent autism. Lancet. 2003; 362:732-734.

Murray ML, Hsia Y, Glaser K, et al. Pharmacological treatments prescribed to people with autism spectrum disorder in primary health care. Psychopharmacology (Berl). 2014; 231:1011- 1021.

Santosh PJ, Singh J. Drug treatment of autism spectrum disorder and its comorbidities in children and adolescents. BJPsych Adv. 2016; 22:151-161.

McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002; 347:314-321.

Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004; 114:e634-e641.

McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH. A double-blind placebocontrolled study of risperidone in adults with autistic disorder and other pervasive de- velopmental disorders. Arch Gen Psychiatry. 1998; 55:633-641.

Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry. 2002; 41:140-147.

Troost PW, Lahuis BE, Steenhuis MP, et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psyc- hiatry. 2005; 44:1137-1144.

Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized placebo-cont- rolled double-blind study. J Child Neurol. 2006; 21:450-455.

Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spect- rum disorders: safety and efficacy. J Child Adolesc Psychopharmacol. 2006; 16:575-587.

Alsayouf HA, Talo H, Biddappa ML, et al. Risperidone or aripiprazole can resolve autism core signs and symptoms in young children: case study. Children. 2021; 8:318.

Blankenship K, Erickson CA, Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6–17 years. Pediatr Health. 2010; 4:375-381.

Marcus RN, Owen R, Kamen L, et al. A placebo-controlled fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009; 48:1110-1119.

Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009; 124:1533-1540.

Ghanizadeh A, Sahraeizadeh A, Berk M. A head-to-head comparison of aripiprazole and ris- peridone for safety and treating autistic disorders. Child Psychiatry Hum Dev. 2014; 45:185- 192.

Lamberti M, Siracusano R, Italiano D, et al. Head-to-head comparison of aripiprazole and risperidone in the treatment of ADHD symptoms in children with autistic spectrum disorder and ADHD. Paediatr Drugs. 2016; 18:319-329.

Wink LK, Early M, Schaefer T, et al. Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole. J Child Adolesc Psychopharma- col. 2014; 24:78-82.

Martin A, Koenig K, Scahill L, Bregman J. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 1999; 9:99-107.

Findling RL, McNamara NK, Gracious BL, et al. Quetiapine in nine youths with autistic di- sorder. J Child Adolesc Psychopharmacol. 2004; 14:287-294.

Corson AH, Barkenbus JE, Posey DJ, Stigler KA, McDougle CJ. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry. 2004; 65:1531-1536.

Hardan AY, Jou RJ, Handen BL. Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disord. 2005; 35:387-391.

Loebel A, Brams M, Goldman RS, et al. Lurasidone for the treatment of irritability associated with autistic disorder. J Autism Dev Disord. 2016; 46:1153-1163.

Golubchik P, Sever J, Weizman A. Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial. Clin Neuropharmacol. 2011; 34:216-219.

Stigler KA, Erickson CA, Mullett JE, Posey DJ, McDougle CJ. Paliperidone for irritability in autistic disorder. J Child Adolesc Psychopharmacol. 2010; 20:75-78.

Kowalski JL, Wink LK, Blankenship K, et al. Paliperidone palmitate in a child with autistic disorder. J Child Adolesc Psychopharmacol. 2011; 21:491-493.

Potenza MN, Holmes JP, Kanes SJ, McDougle CJ. Olanzapine treatment of children, adoles- cents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol. 1999; 19:37-44.

Fido A, Al-Saad S. Olanzapine in the treatment of behavioral problems associated with au- tism: an open-label trial. Med Princ Pract. 2008; 17:415-418.

Kemner C, Willemsen-Swinkels SH, de Jonge M, et al. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol. 2002; 22:455-456.

Malone RP, Cater J, Sheikh RM, et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry. 2001; 40:887-894.

Zuddas A, Ledda MG, Fratta A, Muglia P, Cianchetti C. Clinical effects of clozapine on autistic disorder. Am J Psychiatry. 1996; 153:738.

Chen NC, Bedair HS, McKay B, Bowers MB Jr, Mazure C. Clozapine in the treatment of agg- ression in an adolescent with autistic disorder. J Clin Psychiatry. 2001; 62:479-480.

Lambrey S, Falissard B, Martin-Barrero M, et al. Effectiveness of clozapine for aggression in an adolescent with autistic disorder. J Child Adolesc Psychopharmacol. 2010; 20:79-80.

Gobbi G, Pulvirenti L. Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behavior. J Psychiatry Neurosci. 2001; 26:340-341.

Beherec L, Lambrey S, Quilici G, et al. Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors. J Clin Psychophar- macol. 2011; 31:341-344.

McDougle CJ, Kem DL, Posey DJ. Use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry. 2002; 41:921-927.

Cohen SA, Fitzgerald BJ, Khan SR, Khan A. Effect of a switch to ziprasidone in adults with autistic disorder. J Clin Psychiatry. 2004; 65:110-113.

Goforth HW, Rao MS. Improvement in behaviour and attention in an autistic patient treated with ziprasidone. Aust N Z J Psychiatry. 2003; 37:775-776.

Malone RP, Delaney MA, Hyman SB, Cater JR. Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adolesc Psychopharmacol. 2007; 17:779-790.

Duggal HS. Ziprasidone for maladaptive behavior and ADHD symptoms in autistic disorder. J Child Adolesc Psychopharmacol. 2007; 17:261-263.

Millard PH, McLaren JL, Coffey DB. Lurasidone treatment in a child with autism spectrum disorder with irritability and aggression. J Child Adolesc Psychopharmacol. 2014; 24:354-356.

Gupta M, Hoover G Jr. Lurasidone: an effective alternative for the treatment of irritability associated with autism spectrum disorder. Cureus. 2020; 12:e12360.

Cohen IL, Campbell M, Posner D. A study of haloperidol in young autistic children. Psychop- harmacol Bull. 1980; 16:63-65.

Anderson LT, Campbell M, Grega DM, et al. Haloperidol in the treatment of infantile autism. Am J Psychiatry. 1984; 141:1195-1202.

Locascio JJ, Malone RP, Small AM, et al. Factors related to haloperidol response and dyskine- sias in autistic children. Psychopharmacol Bull. 1991; 27:119-126.

Miral S, Gencer O, Inal-Emiroglu FN, et al. Risperidone versus haloperidol in children and adolescents with autism. Eur Child Adolesc Psychiatry. 2008; 17:1-8.

Gencer O, Emiroglu FN, Miral S, et al. Long-term efficacy and safety of risperidone and halo- peridol in children and adolescents with autistic disorder. Eur Child Adolesc Psychiatry. 2008; 17:217-225.

Naruse H, Nagahata M, Nakane Y, et al. Double-blind trial of pimozide, haloperidol and pla- cebo in children with behavioral disorders. Acta Paedopsychiatr. 1982; 48:173-184.

Ernst M, Gonzalez NM, Campbell M. Acute dystonic reaction with low-dose pimozide. J Am Acad Child Adolesc Psychiatry. 1993; 32:640-642.

Hollander E, Soorya L, Chaplin W, et al. Double-blind placebo-controlled trial of fluoxetine for repetitive behaviors in adult autism spectrum disorders. Am J Psychiatry. 2012 ;169:292- 299.

Hollander E, Phillips A, Chaplin W, et al. Placebo-controlled crossover trial of fluoxetine on repetitive behaviors in childhood autism. Neuropsychopharmacology. 2005; 30:582-589.

Buchsbaum MS, Hollander E, Haznedar MM, et al. Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders. Int J Neuropsychopharmacol. 2001; 4:119-125.

Herscu P, Handen BL, Arnold LE, et al. The SOFIA study: low-dose fluoxetine on repetitive behaviors in children with autistic disorder. J Autism Dev Disord. 2020; 50:3233-3244.

Hellings JA, Kelley LA, Gabrielli WF, Kilgore E, Shah P. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry. 1996; 57:333-336.

Potter LA, Scholze DA, Biag HMB, et al. Randomized controlled trial of sertraline in young children with autism spectrum disorder. Front Psychiatry. 2019; 10:810.

Alolaby RR, Jiraanont P, Durbin-Johnson B, et al. Molecular biomarkers predictive of sertra- line treatment response in young children with autism spectrum disorder. Front Genet. 2020; 11:308.

Namerow L, Thomas P, Bostic JQ, Prince J, Monuteaux MC. Use of citalopram in pervasive developmental disorders. J Dev Behav Pediatr. 2003; 24:104-108.

King BH, Hollander E, Sikich L, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior. Arch Gen Psychiatry. 2009; 66:583- 590.

Owley T, Walton L, Salt J, et al. An open-label trial of escitalopram in pervasive developmen- tal disorders. J Am Acad Child Adolesc Psychiatry. 2005; 44:343-348.

McDougle CJ, Owley T, Brune CW, et al. A pharmacogenetic study of escitalopram in autism spectrum disorders. Autism Res. 2010; 3:1-7.

Coşkun M, Öztürk M, Zoroğlu S. Escitalopram treatment in preschool children with anxiety disorders: a case series. Bull Clin Psychopharmacol. 2012; 22:262-267.

Ong LT, Chee NMZ. Psychopharmacological management of obsessive–compulsive behavi- our in children and adolescents with autism spectrum disorders: a narrative review. Egypt J Neurol Psychiatry Neurosurg. 2024; 60:64.

McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry. 1996; 53:1001-1008.

Martin A, Koenig K, Anderson GM, Scahill L. Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Autism Dev Disord. 2003; 33:77-85.

Sugie Y, Sugie H, Fukuda T, et al. Clinical efficacy of fluvoxamine and functional polymorp- hism in a serotonin transporter gene on childhood autism. J Autism Dev Disord. 2005; 35:377-385.

Posey DJ, Litwiller M, Koburn A, McDougle CJ. Paroxetine in autism. J Am Acad Child Adolesc Psychiatry. 1999; 38:111-112.

Snead RW, Boon F, Presberg J. Paroxetine for self-injurious behavior. J Am Acad Child Ado- lesc Psychiatry. 1994; 33:909-910.

Posey DJ, Guenin KD, Kohn AE, et al. A naturalistic open-label study of mirtazapine in au- tistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2001; 11:267-277.

Coskun M, Karakoc S, Kircelli F, Mukaddes NM. Effectiveness of mirtazapine in inappropri- ate sexual behaviors in individuals with autistic disorder. J Child Adolesc Psychopharmacol. 2009; 19:203-206.

Carminati GG, Deriaz N, Bertschy G. Low-dose venlafaxine in adolescents and young adults with autistic disorder improves self-injurious behavior and ADHD-like symptoms. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30:312-315.

Hollander E, Kaplan A, Cartwright C, Reichman D. Venlafaxine in children, adolescents, and young adults with autism spectrum disorders. J Child Neurol. 2000; 15:132-135.

Carminati GG, Gerber F, Darbellay B, et al. Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2016; 65:85-95.

Gedye A. Trazodone reduced aggressive and self-injurious movements in a mentally handi- capped male patient with autism. J Clin Psychopharmacol. 1991; 11:275-276.

Blackmer AB, Feinstein JA. Management of sleep disorders in children with neurodevelop- mental disorders: a review. Pharmacotherapy. 2016; 36:84-89.

Relia S, Ekambaram V. Pharmacological approach to sleep disturbances in autism spectrum disorders with psychiatric comorbidities: a literature review. Med Sci. 2018; 6:95.

Mammarella V, Orecchio S, Cameli N, et al. Using pharmacotherapy to address sleep distur- bances in autism spectrum disorders. Expert Rev Neurother. 2023; 23:1261-1276.

Kochhar P, Batty MJ, Liddle EB, et al. Autistic spectrum disorder traits in children with atten- tion deficit hyperactivity disorder. Child Care Health Dev. 2011; 37:103-110.

Van der Meer JMJ, Oerlemans AM, Van Steijn DJ, et al. Are autism spectrum disorder and attention-deficit/hyperactivity disorder different manifestations of one disorder? J Am Acad Child Adolesc Psychiatry. 2012; 51:1160-1172.

Grzadzinski R, Dick C, Lord C, Bishop S. Parent-reported and clinician-observed ASD symp- toms in children with ADHD. Mol Autism. 2016; 7:7.

Salazar F, Baird G, Chandler S, et al. Co-occurring psychiatric disorders in preschool and elementary school-aged children with autism spectrum disorder. J Autism Dev Disord. 2015; 45:2283-2294.

Joshi G, Faraone SV, Wozniak J, et al. Symptom profile of ADHD in youth with high-functio- ning autism spectrum disorder. J Atten Disord. 2017; 21:846-855.

Antshel KM, Russo N. Autism spectrum disorders and ADHD: overlapping phenomenology, diagnostic issues, and treatment considerations. Curr Psychiatry Rep. 2019; 21:34.

Scahill L, Bearss K, Sarhangian R, et al. Using a patient-centered outcome measure to test methylphenidate versus placebo in children with autism spectrum disorder. J Child Adolesc Psychopharmacol. 2017; 27:125-131.

Pearson DA, Santos CW, Aman MG, et al. Effects of extended-release methylphenidate tre- atment on ADHD behaviors in children with autism spectrum disorders. J Child Adolesc Psychopharmacol. 2013; 23:337-351.

Pearson DA, Santos CW, Aman MG, et al. Effects of extended-release methylphenidate on cognitive task performance in children with autism spectrum disorder and ADHD. J Child Adolesc Psychopharmacol. 2020; 30:414-426.

Ghuman JK, Aman MG, Lecavalier L, et al. Randomized placebo-controlled crossover study of methylphenidate in preschoolers with developmental disorders. J Child Adolesc Psychopharmacol. 2009; 19:329-339.

Handen BL, Aman MG, Arnold LE, et al. Atomoxetine, parent training, and their combinati- on in children with autism spectrum disorder and ADHD. J Am Acad Child Adolesc Psychi- atry. 2015; 54:905-915.

Eslamzadeh M, Hebrani P, Behdani F, et al. Efficacy of atomoxetine in autism spectrum di- sorders: a randomized double-blind placebo-controlled trial. Iran J Psychiatry Behav Sci. 2018;12.

Fankhauser MP, Karumanchi VC, German ML, Yates A, Karumanchi S. Double-blind place- bo-controlled study of transdermal clonidine in autism. J Clin Psychiatry. 1992; 53:77-82.

Jaselskis CA, Cook EH Jr, Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol. 1992; 12:322-327.

Ming X, Gordon E, Kang N, Wagner GC. Use of clonidine in children with autism spectrum disorders. Brain Dev. 2008; 30:454-460.

Handen BL, Sahl R, Hardan AY. Guanfacine in children with autism and/or intellectual disa- bilities. J Dev Behav Pediatr. 2008; 29:303-308.

Scahill L, McCracken JT, King BH, et al. Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. Am J Psychiatry. 2015; 172:1197-1206.

Politte LC, Scahill L, Figueroa J, et al. Extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms. Neuropsychopharmacology. 2018; 43:1772-1778.

Plioplys AV. Autism: electroencephalogram abnormalities and clinical improvement with valproic acid. Arch Pediatr Adolesc Med. 1994; 148:220.

Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S. Open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry. 2001; 62:530-534.

Hellings JA, Weckbaugh M, Nickel EJ, et al. Double-blind placebo-controlled study of valpro- ate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychop- harmacol. 2005; 15:682-692.

Hollander E, Chaplin W, Soorya L, et al. Divalproex sodium vs placebo for irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology. 2010; 35:990-998.

Siegel M, Beresford CA, Bunker M, et al. Preliminary investigation of lithium for mood di- sorder symptoms in children and adolescents with autism spectrum disorder. J Child Adolesc Psychopharmacol. 2014; 24:399-402.

Serret S, Thummler S, Dor E, et al. Lithium as rescue therapy for regression and catatonia in SHANK3 patients with autism spectrum disorder. BMC Psychiatry. 2015; 15:107.

Belsito KM, Law PA, Kirk KS, Landa RJ, Zimmerman AW. Lamotrigine therapy for autistic disorder: randomized placebo-controlled trial. J Autism Dev Disord. 2001; 31:175-181.

Limbu B, Deb S, Roy M, et al. Randomised controlled trials of mood stabilisers for people with autism spectrum disorder: systematic review and meta-analysis. BJPsych Open. 2022; 8:e52.

Rugino TA, Samsock TC. Levetiracetam in autistic children: an open-label study. J Dev Behav Pediatr. 2002; 23:225-230.

Wasserman S, Iyengar R, Chaplin WF, et al. Levetiracetam versus placebo in childhood au- tism. Int Clin Psychopharmacol. 2006; 21:363-367.

Mazzone L, Ruta L. Topiramate in children with autistic spectrum disorders. Brain Dev. 2006; 28:668.

Rezaei V, Mohammadi MR, Ghanizadeh A, et al. Double-blind placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 34:1269-1272.

Fuentes J, Hervás A, Howlin P, et al. ESCAP practice guidance for autism: evidence-based re- commendations for diagnosis and treatment. Eur Child Adolesc Psychiatry. 2021; 30:961-984.

Huang Y, Huang X, Ebstein RP, Yu R. Intranasal oxytocin in the treatment of autism spectrum disorders: a multilevel meta-analysis. Neurosci Biobehav Rev. 2021; 122:18-27.

Lemonnier E, Degrez C, Phelep M, et al. Randomised controlled trial of bumetanide in au- tism in children. Transl Psychiatry. 2012;2:e202.

Sprengers JJ, van Andel DM, Zuithoff NP, et al. Bumetanide for core symptoms of autism spectrum disorder (BAMBI). J Am Acad Child Adolesc Psychiatry. 2021; 60:865-876.

Ghaleiha A, Asadabadi M, Mohammadi MR, et al. Memantine as adjunctive treatment to ris- peridone in children with autistic disorder. Int J Neuropsychopharmacol. 2013; 16:783-789.

Brignell A, Marraffa C, Williams K, May T. Memantine for autism spectrum disorder. Coch- rane Database Syst Rev. 2022;8:CD013845.

Chez MG, Aimonovitch M, Buchanan T, et al. Rivastigmine tartrate in children with autistic spectrum disorders. J Child Neurol. 2004; 19:165-169.

Ure A, Cox GR, Haslam R, Williams K. Acetylcholinesterase inhibitors for autistic spectrum disorders. Cochrane Database Syst Rev. 2023;6:CD013851.

Fortini PS, Toibaro JJ, Caraballo RH. Purified cannabidiol improves severe treatment-resis- tant behavioral symptoms in children with autism spectrum disorder. Pharmacol Biochem Behav. 2025; 249:173971.